Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

PURPOSE: The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Res Treat
Main Authors: Boonsri, Boonyakorn, Yacqub-Usman, Kiren, Thintharua, Pakpoom, Myint, Kyaw Zwar, Sae-Lao, Thannicha, Collier, Pam, Suriyonplengsaeng, Chinnawut, Larbcharoensub, Noppadol, Balasubramanian, Brinda, Venkatraman, Simran, Egbuniwe, Isioma U., Gomez, Dhanwant, Mukherjee, Abhik, Kumkate, Supeecha, Janvilisri, Tavan, Zaitoun, Abed M, Kuakpaetoon, Thiti, Tohtong, Rutaiwan, Grabowska, Anna M, Bates, David O., Wongprasert, Kanokpan
Formato: Artigo
Idioma:Inglês
Publicado: Korean Cancer Association 2021
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053863/
https://ncbi.nlm.nih.gov/pubmed/33070556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2020.585
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares